Resources from the same session
1616O - Nab-paclitaxel plus gemcitabine versus modified FOLFIRINOX or S-IROX in metastatic or recurrent pancreatic cancer (JCOG1611, GENERATE): A multicentred, randomized, open-label, three-arm, phase II/III trial
Presenter: Akihiro Ohba
Session: Proffered Paper session 2 - Gastrointestinal tumours, upper digestive
Resources:
Abstract
Slides
Webcast
LBA83 - Neoadjuvant chemotherapy with FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy for borderline resectable and resectable pancreatic cancer (PREOPANC-2): A multicenter randomized controlled trial
Presenter: Bas Groot Koerkamp
Session: Proffered Paper session 2 - Gastrointestinal tumours, upper digestive
Resources:
Abstract
Slides
Webcast
Invited Discussant 1616O and LBA83
Presenter: Angela Lamarca
Session: Proffered Paper session 2 - Gastrointestinal tumours, upper digestive
Resources:
Slides
Webcast
Q&A
Presenter: All Speakers
Session: Proffered Paper session 2 - Gastrointestinal tumours, upper digestive
Resources:
Webcast
LBA76 - The primary results of an intergroup phase III randomized controlled trial comparing ramucirumab plus irinotecan with irinotecan in the third or later line treatment beyond progression after ramucirumab for advanced gastric cancer (RINDBeRG trial)
Presenter: Shigenori Kadowaki
Session: Proffered Paper session 2 - Gastrointestinal tumours, upper digestive
Resources:
Abstract
Slides
Webcast
LBA77 - 5-fluorouracil and oxaliplatin with or without docetaxel in the first-line treatment of HER2 negative locally advanced (LA) unresectable or metastatic gastric or gastro-esophageal junction (GEJ) adenocarcinoma (GASTFOX-PRODIGE 51): A randomized phase III trial sponsored by the FFCD
Presenter: Aziz Zaanan
Session: Proffered Paper session 2 - Gastrointestinal tumours, upper digestive
Resources:
Abstract
Slides
Webcast
Q&A
Presenter: All Speakers
Session: Proffered Paper session 2 - Gastrointestinal tumours, upper digestive
Resources:
Webcast